
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Diagnosing occupational dermatitis is often a cumbersome task but a seven-point checklist is available to make it less daunting, Denis Sasseville, M.D., said.